SCHEMBL3769372

SCHEMBL3769372

Cc1ccc(C(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 5/20 0.49
L3MBTL1 Q9Y468 5/20 0.49
ALDH1A1 P00352 3/20 0.46
USP2 O75604 1/20 0.46
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HRH3 Q9Y5N1 4/20 0.44
TP53BP1 Q12888 1/20 0.44
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 1/20 0.42
TP53 P04637 1/20 0.42
PARP1 P09874 1/20 0.42
MBTD1 Q05BQ5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773969 0.91 L3MBTL3 (0.49) L3MBTL3L3MBTL1ALDH1A1USP2HTT
SCHEMBL3768371 0.87 ALDH1A1 (0.45) L3MBTL3L3MBTL1ALDH1A1USP2HTT
SCHEMBL3767212 0.86 HTT (0.56) L3MBTL3L3MBTL1ALDH1A1HTTNPSR1
SCHEMBL3766156 0.86 USP2 (0.62) L3MBTL3L3MBTL1ALDH1A1USP2HRH3
SCHEMBL3765908 0.85 CCR5 (0.45) L3MBTL3L3MBTL1ALDH1A1USP2HTT
SCHEMBL3767940 0.84 SMN1; SMN2 (0.50) ALDH1A1USP2HTTNPSR1LMNA
SCHEMBL3762910 0.84 ALDH1A1 (0.54) L3MBTL3L3MBTL1ALDH1A1USP2HRH3
SCHEMBL3763252 0.82 SMN1; SMN2 (0.50) ALDH1A1USP2HTTNPSR1KDM4E
SCHEMBL3772241 0.82 SMN1; SMN2 (0.61) ALDH1A1HTTLMNASMN1; SMN2TP53
SCHEMBL3772875 0.82 FNTA (0.51) L3MBTL3L3MBTL1ALDH1A1HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 L3MBTL3 1357/4885L3MBTL1 1468/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.